Results 21 to 30 of about 74,496 (193)
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Pharmacological Research, 2022 The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj +1 more source
Haematologica, 2017 In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski +10 more
doaj +1 more source
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Haematologica, 2014 Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics +13 more
doaj +1 more source
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 [PDF]
Leukemia, 2020 La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–15. https://doi.org/10.1038/s41375-020-0891-0. CAS Article PubMed Google Scholar Download references Division of Hematology, University of Siena, Siena, Italy ...
Gozzetti, Alessandro +2 more
openaire +4 more sources
Polisitemia vera; aspek klinis dan tatalaksana terbaru
JKS (Jurnal Kedokteran Syiah Kuala), 2020 Abstrak. Polisitemia Vera (PV) adalah gangguan kronis klonal mieloproliperatif yang ditandai dengan peningkatan hebat dalam jumlah sel darah merah dan volume darah total, dan biasanya disertai dengan leukositosis, trombositosis dan splenomegali.
Muhammad Riswan +2 more
doaj +1 more source
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease [PDF]
, 2017 Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract.
de Jonge, Wouter +3 more
core +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire +1 more source
BMC Infectious Diseases, 2021 Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz +6 more
doaj +1 more source
In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue : role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways [PDF]
, 2009 Visfatin is an adipogenic adipokine with increased levels in obesity, properties common to leptin. Thus, leptin may modulate visfatin production in adipose tissue (AT).
Brown, James +17 more
core +1 more source
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) [PDF]
, 2021 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 (coronavirus disease 2019), which is associated with high morbidity and mortality, especially in elder patients. Acute respiratory distress syndrome (ARDS) is a life-threatening
Meyn, Damaris +15 more
core +1 more source